Core Viewpoint - The company, Zhongji Changshou Science (00767), plans to acquire 25% of the issued share capital of Asia Comprehensive Cell Bank Limited for an initial consideration of HKD 300 million, with the option to issue up to HKD 300 million in non-redeemable convertible bonds to finance the acquisition [1] Group 1: Acquisition Details - The acquisition is set to take place on December 1, 2025, and will be financed through a combination of cash and convertible bonds [1] - Asia Comprehensive Cell Bank Limited specializes in high-end customized stem cell and IPSC storage services, catering primarily to high-net-worth individuals in Hong Kong and mainland China [1] Group 2: Business Operations - The target company operates under various trade names, including Weisman Academician International Advanced Medical Center and Asia International Medical Testing Center, employing a team of registered doctors and laboratory technicians [1] - The company provides preclinical immunotherapy services and testing, indicating a focus on advanced medical solutions [1] Group 3: Market Potential - The board believes that stem cell and IPSC storage services, along with cellular immunotherapy medical services, represent a high-growth potential business area [1] - Cellular immunotherapy services are experiencing exponential growth, driven by increasing consumer demand and investment interest in advanced skin regeneration, comprehensive vitality enhancement, and proactive health management strategies [1]
中基长寿科学拟3亿港元收购亚洲综合细胞库有限公司25%股权